VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Recommendation of “Reduce” from Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have received an average recommendation of “Reduce” from the five analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $0.95.

A number of brokerages recently weighed in on VTGN. Wall Street Zen lowered shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd.

Institutional Trading of VistaGen Therapeutics

Several large investors have recently made changes to their positions in VTGN. Virtu Financial LLC purchased a new position in VistaGen Therapeutics in the 4th quarter valued at $25,000. Cubist Systematic Strategies LLC acquired a new stake in shares of VistaGen Therapeutics in the first quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of VistaGen Therapeutics in the third quarter worth about $39,000. Seven Fleet Capital Management LP purchased a new position in shares of VistaGen Therapeutics in the fourth quarter worth about $42,000. Finally, Tudor Investment Corp ET AL acquired a new position in VistaGen Therapeutics during the fourth quarter worth about $50,000. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

VistaGen Therapeutics Stock Performance

Shares of NASDAQ:VTGN remained flat at $0.25 during trading on Friday. The stock had a trading volume of 4,377,172 shares, compared to its average volume of 4,163,570. The stock has a market cap of $10.21 million, a price-to-earnings ratio of -0.14 and a beta of 0.40. VistaGen Therapeutics has a 52-week low of $0.20 and a 52-week high of $5.14. The stock has a fifty day simple moving average of $0.59 and a 200-day simple moving average of $0.66.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Monday, June 15th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). The business had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.40 million. VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.During the same period in the previous year, the company earned ($1.67) earnings per share. As a group, research analysts predict that VistaGen Therapeutics will post -1.32 earnings per share for the current fiscal year.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.